Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Analysts have lifted their price target on Phibro Animal Health by $4, while the model fair value remains at $48.50. That gap reflects a refreshed research view, with some seeing a more attractive balance between risk and reward and others still highlighting execution and valuation sensitivity as key watchpoints. As you read on, you will see how this evolving narrative might shape your own thinking on the stock over time.
Stay updated as the Fair Value for Phibro Animal Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Phibro Animal Health.
Morgan Stanley has lifted its price target on Phibro Animal Health by $4, signaling a refreshed view that the current share price leaves room for upside relative to its own assessment of the business.
The higher target from Morgan Stanley suggests the firm sees a more balanced trade off between risk and potential reward, which some investors may read as increased conviction in management’s ability to execute on its plans.
For valuation focused readers, the revised target helps frame where one major institution believes the shares could reasonably trade based on its research inputs and assumptions.
Even with the $4 increase, the Morgan Stanley work still flags execution as a key watchpoint, hinting that the path to delivering on its assumptions may not be straightforward.
The gap between the street target move and the unchanged model fair value of $48.50 underlines that some analysts remain sensitive to valuation and prefer a margin of safety before turning more constructive.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqGM:PAHC 1-Year Stock Price Chart
We’ve flagged 1 risk for Phibro Animal Health. See which could impact your investment.
Phibro Animal Health issued fiscal 2026 guidance, calling for net sales between US$1.45b and US$1.50b.
The company expects fiscal 2026 net income in a range of US$85m to US$95m and diluted EPS of US$2.08 to US$2.32.
Phibro announced that CEO Jack C. Bendheim will step down as Chief Executive Officer on July 1, 2026, becoming Executive Chairman while remaining Chairman of the Board.
On the same date, Daniel Bendheim, currently Executive Vice President, Corporate Strategy, will take over as Chief Executive Officer and President, continuing to lead the Phibro Forward efficiency and growth program.
Story Continues